All In Biotech

Drug Trial Radar · NCT07340138

Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis

A Phase 1b Study of Pelabresib (DAK539) add-on to Stable Dose of Ruxolitinib in Japanese Adult Patients With Myelofibrosis

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

3

Actual

Start

Apr 15, 2026

Primary completion

Jul 23, 2026

Study completion Sep 21, 2030

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jan 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 1b, multicenter, open-label study aims to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of pelabresib as add-on to ruxolitinib in Japanese patients with myelofibrosis (MF).

Conditions

  • Primary Myelofibrosis (PMF)
  • Post-polycythemia Vera Myelofibrosis (Post-PV MF)
  • Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Interventions

  • PelabresibDrug

    125 mg orally once daily (QD) on Days 1-14 of each 21-day cycle

  • RuxolitinibDrug

    5-25 mg twice daily (BID)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicities (DLTs)Time frame: Up to 21 days
  2. Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)Time frame: Through study completion, an average of approximately 4 years

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Kamogawa, Chiba, Japan

  • Novartis Investigative Site

    Sapporo, Hokkaido, Japan

  • Novartis Investigative Site

    Chūō, Yamanashi, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.